Skip to main content
OPCHOption Care Health, Inc.Sell5.5·$23.50+4.54%
SellModerate Confidence
Investment thesis

Option Care Health offers attractive valuation and consistent earnings execution, but heavy customer and supplier concentration alongside declining earnings estimates and a confirmed downtrend keep the risk profile elevated.

Thesis pillars

  • Attractive Valuation EntryDeteriorating
  • Customer Concentration RiskDeteriorating
  • Earnings Estimates DecliningDeteriorating
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Option Care Health, Inc. (OPCH) Stock Analysis

Recovery setup

SellQualityModerate Confidence

Healthcare · Medical Care Facilities

Sell if holding. At $23.50, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors.

Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies plus 109 stand-alone ambulatory infusion suites—delivering anti-infective, immunoglobulin, and biologic therapies under physician direction. Revenue comes from... Read more

$23.50+2.1% A.UpsideScore 5.5/10#24 of 36 Medical Care Facilities
QualityF-score7 / 9FCF yield4.78%
Stop $22.41Target $24.43(analyst − 13%)A.R:R 0.1:1
Analyst target$28.08+19.5%12 analysts
$24.43our TP
$23.50price
$28.08mean
$39

Sell if holding. At $23.50, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors. Chart setup: Death cross but MACD improving, RSI 72. Score 5.5/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, news boost earnings 0.60, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-29
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Jul 29, 2026· next earnings call

Thesis

Rewards
Attractive valuation
Positive momentum
Positive insider activity
Risks
Concentration risk — Customer: MCOs and non-governmental payers (88.0%)
Concentration risk — Supplier: four vendors
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)17.0
P/E (Fwd)11.0
Mkt Cap$3.5B
EV/EBITDA11.5
Profit Mgn3.6%
ROE15.3%
Rev Growth1.3%
Beta0.65
DividendNone
Rating analysts19

Quality Signals

Piotroski F7/9

Options Flow

P/C0.28bullish
IV84%elevated

Concentration Risks(10-K Item 1A)

  • HIGHCustomerMCOs and non-governmental payers88%
    10-K Item 1A: '88% of our revenue came from MCOs and other non-governmental payers'
  • LOWCustomerlargest payer14%
    10-K Item 1: 'The Company's largest payer represented approximately 14% of its revenue for the year ended December 31, 2025.'
  • LOWregulatoryMedicare and Medicaid12%
    10-K Item 1: 'approximately 12% of the Company's revenue was reimbursable through direct government healthcare programs, such as Medicare and Medicaid.'
  • HIGHSupplierfour vendors
    10-K Item 1A: 'approximately 68% of our pharmaceutical and medical supply purchases were from four vendors'

Material Events(8-K, last 90d)

  • 2026-05-05Item 5.02LOW
    Chief Growth Officer Christopher L. Grashoff to depart effective May 8, 2026. Entitled to separation benefits under the Amended and Restated Executive Severance Plan conditioned on release of claims. No successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.0
Support Resistance
2.4
52w Position
3.0
Gap
3.0
Extreme gap up (6.5%) - may pull back

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
2.7
Revenue Growth
2.8
GatesA.R:R 0.1 < 1.5@spotDeath cross (50MA < 200MA)Executive change: officer departure/appointmentMomentum 7.9>=5.5Insider activity: OKNEWS BOOST EARNINGS 0.60EARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
72 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $20.68Resistance $24.96

Price Targets

$22
$24
A.Upside+2.1%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (2.1% upside)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-29 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OPCH stock a buy right now?

Sell if holding. At $23.50, A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors. Chart setup: Death cross but MACD improving, RSI 72. Prior stop was $22.41. Score 5.5/10, moderate confidence.

What is the OPCH stock price target?

Take-profit target: $24.43 (+2.1% upside). Prior stop was $22.41. Stop-loss: $22.41.

What are the risks of investing in OPCH?

Concentration risk — Customer: MCOs and non-governmental payers (88.0%); Concentration risk — Supplier: four vendors; Analyst target reached - limited upside remaining.

Is OPCH overvalued or undervalued?

Option Care Health, Inc. trades at a P/E of 17.0 (forward 11.0). TrendMatrix value score: 7.0/10. Verdict: Sell.

What do analysts say about OPCH?

19 analysts cover OPCH with a consensus score of 4.1/5. Average price target: $28.

What does Option Care Health, Inc. do?Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies...

Option Care Health operates 196 home and alternate-site infusion pharmacies in 43 states—87 full-service pharmacies plus 109 stand-alone ambulatory infusion suites—delivering anti-infective, immunoglobulin, and biologic therapies under physician direction. Revenue comes from reimbursements by MCOs, Medicare, Medicaid, and commercial payers for pharmaceuticals dispensed and nursing services, with 6,528 full-time and 1,738 part-time employees at year-end 2025.

Related stocks: NUTX (Nutex Health Inc.) · THC (Tenet Healthcare Corporation) · SRTA (Strata Critical Medical, Inc.) · ASTH (Astrana Health Inc.) · EHC (Encompass Health Corporation)
Home Stocks OPCH

Latest news

Latest News

TradingKey2d ago
GuruFocus92d ago
Yahoo Finance92d agoEarnings
TipRanks92d ago
MarketBeat9d agoEarnings
MarketBeat9d ago
Cổng thông tin điện tử tỉnh Tây Ninh99d ago
Yahoo Finance99d ago
Yahoo Finance2d agoEarnings
MarketBeat3d ago
MarketBeat3d ago
Yahoo Finance100d agoEarnings
StockStory91d ago
Yahoo Finance91d agoEarnings
Finviz91d ago
GuruFocus91d ago
The Malone Telegram91d agoLegal
Quiver Quantitative91d ago
GlobeNewswire91d agoLegal
Seeking Alpha91d ago
Loading more...